EquityFlow
›
Companies
› Purespring
Purespring
Biotech
· London, GB
Developer of gene therapies targeting kidney disease.
Funding history
Date
Round
Amount
Oct 2024
Series B
Purespring, a London gene-therapy biotech for kidney disease, raised a GBP80M Series B led by Sofinnova Partners.
$102M
Investors
Forbion
Gilde Healthcare
Sofinnova Partners
Syncona Limited
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →